ERBB2 and breast carcinoma: This is the first randomized clinical dataset to demonstrate the clinical benefit of capivasertib–fulvestrant in a Chinese cohort of patients with HR-positive/HER2-negative advanced breast cancer; most patients were part of a dedicated extended study cohort for whom data have not been previously published.